论文部分内容阅读
侵袭性肺曲菌病(IPA)是癌症患者白细胞减少期间常见的严重感染之一,死亡率达50％以上,为确定两性霉素B雾化吸入预防IPA的价值,作者对一组病例进行了前瞻性研究。 115例癌症患者中,AML67例,ALL复发或高度恶性淋巴瘤11例,接受大剂量化疗的实体瘤患者37例。将病人随机分为治疗组(Ⅰ组)及非治疗组(Ⅱ组)。Ⅰ组65例,在中性粒细胞减少(<500/μl)>10天后开始予10mg两性霉素B雾化吸入,每日2次,每次15～20分钟,用至中性粒细胞连续2天>1000/μl后停用。Ⅱ组50例,未接受两性霉素B雾化治疗。 结果 两组共9例发生IPA,其中Ⅰ组3例(5％)。Ⅱ组6倒(12％),P>0.05。9例IPA中的6例(67％)
Invasive pulmonary aspergillosis (IPA) is one of the most common serious infections during leukopenia in cancer patients. The mortality rate is more than 50%. To determine the value of amphotericin B nebulization in the prevention of IPA, the authors performed a series of cases. Prospective study. Of the 115 cancer patients, 67 were AML, 11 were ALL with relapsed or high-grade lymphoma, and 37 patients were treated with high-dose chemotherapy. The patients were randomly divided into treatment group (group I) and non-treatment group (group II). In Group I, 65 patients were treated with 10 mg amphotericin B nebulized twice daily for 15-20 minutes after neutropenia (<500/μl)> 10 days after neutropenia (<500/μl). Deactivate after 2 days > 1000/μl. In group II, 50 patients did not receive atomization of amphotericin B. Results IPA occurred in 9 patients in both groups, including 3 patients in group I (5%). Group II was down (12%), P>0.05, and 6 out of 9 cases of IPA (67%)